Mead Johnson Nutrition
Mead Johnson Nutrition's (MJN) IPO was an anomaly, Walker says. As the first deal of 2009, investors were eager to grasp on to any good news coming out of the market.
"For this reason its weight is disproportionate to the rest of the group," Walker says. "It is similar to when Visa (V)came to market in 2008. Mead is a well-known name that already has market penetration."
A subsidiary of Bristol-Myers Squibb (BMY), Mead Johnson Nutrition makes formula for infants, most notably under the name Enfamil, as well as nutrition products for children.On February 11, the company offered 30 million shares at $24 apiece, to raise $720 million. Bristol-Myers said it spun off Mead to help accelerate its growth. In the third quarter, earnings slid 5% to $97.6 million, due to weak sales in North America and Europe. As a result of the Mead's IPO, it now has more stock available, and its per-share profit tumbled 21% to 48 cents from 61 cents. Excluding one-time costs and benefits, the company said it earned 53 cents a share. Revenue fell 6% to $699.8 million from $742.8 million. Since its IPO, Mead's stock has soared 87.5% to close at $44.99 on Jan. 4. In the fall it announced that it will begin making powder infant formula, which should be available next year. Last month, Bristol-Myers split off its holdings in the company. The stock swap allowed Bristol-Myers shareholders to exchange some, all or none of their shares for Mead stock tax-free and at a discount. For each $1 of Bristol-Myers stock swapped, shareholders received about $1.11 worth of Mead shares.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV